市場調查報告書
商品編碼
1290872
避孕藥市場:現狀分析與預測(2022-2028年)Contraceptive Pills Market: Current Analysis and Forecast (2022-2028) |
由於人口增長、計劃生育需求增加以及避孕意識提高,避孕藥市場預計將以 6% 左右的穩定速度增長。
為了更好地了解避孕藥行業的市場採用情況,將市場細分為北美(美國、加拿大、北美其他地區)、歐洲(德國、英國、法國、西班牙、意大利、歐洲其他地區)、亞洲太平洋地區(中國、日本)、印度、亞太地區其他地區)以及世界其他地區。預計北美在預測期內將以顯著的複合年增長率增長。這主要是由於該地區 15-44 歲女性人口的增加以及意識的提高。此外,由於仿製藥和低成本設備的推出,青少年對避孕藥具的需求正在增加。例如,據 Mayne Pharma 稱,2021 年 4 月,NEXSTELLIS 獲得美國食品和藥物管理局的批准。它是第一個也是唯一一個含有 E4 的避孕藥,E4 是一種從植物中合成的天然雌激素,具有獨特的作用機制。
Contraceptive pills, also known as birth control pills, are medications taken orally by women to prevent pregnancy. These pills contain hormones (either a combination of estrogen and progestin or progestin alone) that work to prevent ovulation, the release of an egg from the ovaries. The contraceptive pills market has witnessed steady growth over the past few years due to various factors such as increasing awareness about contraception, the availability of different types of pills, and the rise in sexually active women. The market is driven by factors such as the need for effective family planning, government initiatives to promote contraception, and a rise in the prevalence of sexually transmitted infections (STIs). For instance, as per WHO, around 374 million new cases with 1 of 4 STIs were diagnosed in 2020.
The contraceptive pills market is expected to grow at a steady rate of around 6% owing to the increasing population, the growing demand for family planning, and rising awareness about contraception. For instance, in 2021, Healthy Native Youth announced a sexual health program for American Indian and Alaska Native (AI/AN) youth. Additionally, the development of new formulations, such as extended-cycle pills, low-dose pills, and progestin-only pills, has expanded the market further.
Based on type, the market is segmented into combines contraceptive pills and progestin pills. As per our market study, the combines contraceptive pills category is expected to dominate the contraceptive pills market during the forecast period owing to its high effectiveness rate and convenience for women. Combination pills contain a combination of synthetic estrogen and progestin hormones, which work together to prevent ovulation, thicken cervical mucus to block sperm from reaching the egg, and thin the lining of the uterus to prevent the implantation of a fertilized egg.
On the basis of distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, clinics, online channel, public channel & NGOS, and others. Among these, the retail pharmacy category held the highest share of this market in 2021. This is mainly due to the rising awareness about various forms of contraception and increasing sales of OTC contraceptives, etc. Additionally, growing demand for the improved online distribution channel by collaborating with local sellers will further drive the growth of the market during the forecast period.
For a better understanding of the market adoption of the contraceptive pills industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the increasing women population within the age group of 15-44 years, and growing awareness in the region. Moreover, the launch of generic and low-cost drugs and devices has also led to an increase in the demand for contraceptives by teenagers. For instance, In April 2021, as per Mayne Pharma, the Food and Drug Administration approved NEXSTELLIS. That is the first and only contraceptive drug that contains E4, a naturally occurring estrogen that is now synthesized from a plant source and has a unique mode of action.
Some of the major players operating in the market include: Pfizer Inc.; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd.; AbbVie Inc.; Bayer AG; Janssen Global Services, LLC; HLL Lifecare Limited; Mylan N.V.; Piramal Enterprises Ltd.; Amneal Pharmaceuticals LLCincreasing